Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) PT at $3.83

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have earned an average recommendation of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $3.8333.

A number of analysts have commented on SGMO shares. Barclays reiterated an “equal weight” rating and issued a $1.00 price objective (down previously from $5.00) on shares of Sangamo Therapeutics in a report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sangamo Therapeutics in a report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday, September 4th. Finally, Wall Street Zen lowered Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th.

Sangamo Therapeutics Stock Down 1.9%

Shares of SGMO opened at $0.43 on Tuesday. Sangamo Therapeutics has a 52-week low of $0.38 and a 52-week high of $2.82. The stock has a market cap of $144.69 million, a PE ratio of -0.98 and a beta of 1.41. The firm’s fifty day moving average is $0.52 and its two-hundred day moving average is $0.54.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.08). The business had revenue of $0.58 million during the quarter, compared to analyst estimates of $34.40 million. Sangamo Therapeutics had a negative net margin of 331.28% and a negative return on equity of 813.95%. As a group, research analysts anticipate that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of SGMO. R Squared Ltd acquired a new position in Sangamo Therapeutics in the 2nd quarter valued at about $28,000. World Investment Advisors raised its position in shares of Sangamo Therapeutics by 88.5% during the 3rd quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 20,000 shares during the period. Caption Management LLC purchased a new stake in shares of Sangamo Therapeutics during the 1st quarter valued at approximately $37,000. XTX Topco Ltd acquired a new position in Sangamo Therapeutics in the second quarter valued at approximately $41,000. Finally, Engineers Gate Manager LP grew its position in Sangamo Therapeutics by 101.7% in the second quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 44,078 shares during the period. 56.92% of the stock is currently owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.